Skip to main content
SpringerLink
Log in

Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this study was to investigate amrubicin (AMR) monotherapy as a salvage therapy for EPNEC arising from digestive organs.

Methods

Patients with EPNEC of the digestive organs who had prior platinum-based chemotherapy and were subsequently treated with AMR between July 2005 and December 2013 at any one of four institutions were retrospectively examined to characterize the safety and efficacy of AMR.

Results

Thirteen patients (ten males, three females; median age 64 years) were examined. Primary cancer sites included stomach (n = 6), rectum (n = 3), esophagus (n = 2), liver (n = 1) and pancreas (n = 1). Prior irinotecan- and etoposide-containing chemotherapies were used in ten and six patients, respectively. Median initial dose of AMR was 40 mg/m2/day for three consecutive days, and median of treatment cycles was 4 (range 1–9). The objective response rate (ORR) was 38.5 %. Median progression-free survival (PFS) and overall survival (OS) were 107 (range 22–275) and 215 days (range 71–535), respectively. Common severe adverse events (grade 3/4) were neutropenia (84.6 %) and febrile neutropenia (30.8 %). Patient with longer platinum-free interval (>90 days) exhibited longer PFS and OS than those with shorter platinum-free interval (190 vs. 63 days and 348 vs. 145 days, respectively).

Conclusions

AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bosman FT, Carbeuri F, Hruban RH, Theise ND (2010) WHO classification of tumors of the digestive system, 4th edn. WHO Press, Geneva, pp 13–14

    Google Scholar 

  2. Brenner B, Tang LH, Shia J, Klimstra DS, Kelsen DP (2007) Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol 34:43–50

    Article  CAS  PubMed  Google Scholar 

  3. Sundstrom S, Bremnes RM, Kaasa S et al (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. J Clin Oncol 20:4665–4672

    Article  CAS  PubMed  Google Scholar 

  4. Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91

    Article  CAS  PubMed  Google Scholar 

  5. von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667

    Google Scholar 

  6. O’Brien ME, Ciuleanu TE, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447

    Article  PubMed  Google Scholar 

  7. Inoue A, Sugawara S, Yamazaki K et al (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401–5406

    Article  CAS  PubMed  Google Scholar 

  8. von Pawel J, Ardizzoni A, Thatcher N (2003) The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed small cell lung cancer (SCLC): a review of 631 patients treated with iv topotecan in 6 studies. Lung Cancer 41(Suppl. 2):S235

    Article  Google Scholar 

  9. Isobe T, Yanai S, Kusaba H et al (2009) Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver. Case Rep Med. doi:10.1155/2009/538081

    PubMed Central  PubMed  Google Scholar 

  10. Maru DM, Khurana H, Rashid A et al (2008) Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 32:1404–1411

    Article  PubMed  Google Scholar 

  11. Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 81:1351–1355

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH (1989) Combined small-cell and non-small-cell lung cancer. J Clin Oncol 7:607–612

    CAS  PubMed  Google Scholar 

  13. Matsui K, Kitagawa M, Miwa A, Kuroda Y, Tsuji M (1991) Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases. Am J Gastroenterol 86:1167–1175

    CAS  PubMed  Google Scholar 

  14. NCCN lung 2014: NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors, version 2.2014 (HGNET1)

  15. Ettinger DS, Jotte R, Lorigan P et al (2010) Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28:2598–2603

    Article  PubMed  Google Scholar 

  16. von Pawel J, Jotte R, Spigel DR et al (2014) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32:4012–4020

    Article  Google Scholar 

  17. Murakami H, Yamamoto N, Shibata T et al (2014) A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer 84:67–72

    Article  PubMed  Google Scholar 

  18. Asayama M, Fuse N, Yoshino Y et al (2011) Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases. Cancer Chemother Pharmacol 68:1325–1330

    Article  CAS  PubMed  Google Scholar 

  19. Eckardt JR, von Pawel J, Pujol JL et al (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–2092

    Article  CAS  PubMed  Google Scholar 

  20. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell-lines. Cancer Res 50:7962–7965

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Kenichi Nishiyama, Department of Anatomic Pathology, Japanese Red Cross Fukuoka Hospital, for providing a clinical sample. We also thank the medical staff of each institution who contributed to treatment of the patients.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan

    Kenta Nio, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Shingo Tamura, Hiroshi Ariyama & Koichi Akashi

  2. Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan

    Shuji Arita & Eishi Baba

  3. Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan

    Kenichi Kohashi & Yoshinao Oda

  4. Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-Ku, Fukuoka, 811-1347, Japan

    Tatsuhiro Kajitani & Taito Esaki

  5. Department of Hematology and Oncology, Japan Community Health Care Organization Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-Ku, Kitakyushu, 806-8501, Japan

    Gen Hirano & Akitaka Makiyama

  6. Department of Oncology, Hamanomachi Hospital, 3-3-1 Nagahama, Chuo-Ku, Fukuoka, 810-8539, Japan

    Kenji Mitsugi

Authors
  1. Kenta Nio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuji Arita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taichi Isobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hitoshi Kusaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenichi Kohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tatsuhiro Kajitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shingo Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gen Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kenji Mitsugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akitaka Makiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Taito Esaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroshi Ariyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshinao Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Koichi Akashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Eishi Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eishi Baba.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nio, K., Arita, S., Isobe, T. et al. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemother Pharmacol 75, 829–835 (2015). https://doi.org/10.1007/s00280-015-2706-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2706-y

Keywords

Search

Navigation